Evaluating for pentosan polysulfate maculopathy at a single academic institution
Authors:
Open Access
- 1 July 2025
- journal article
- Published by SAGE Publications in Therapeutic Advances in Ophthalmology
- Vol. 17
Abstract
Purpose: To report the practices and outcomes of ophthalmic evaluations for pentosan polysulfate sodium (PPS) maculopathy at a single institution. Methods: This study was conducted on patients of Massachusetts Eye and Ear who had documented PPS exposure and an ophthalmic encounter from 2019 through 2022. The main outcomes were examination components performed and identification of PPS maculopathy. Image analysis confirmed findings. Results: Thirty-seven patients were included. Of the initial encounters, optical coherence tomography (OCT) was documented for 29 (78.4%) patients, fundus autofluorescence (FAF) for 13 (35.1%), and color fundus photography (CFP) for 12 (32.4%). Four cases (10.8%) of PPS maculopathy were observed. Mean (range) duration of exposure was 17 (15–20), and mean (range) cumulative exposure was 2418 (2190–2628) mg. Maculopathy did not occur until after 15 years of exposure and greater than 2000 mg of cumulative exposure. Three cases (8.1%) of PPS maculopathy were evaluated following drug cessation over a mean of 18.3 months. Two cases (5.4%) of PPS maculopathy progression post-cessation over durations of 1.1 and 4.3 years were described. Conclusion: We found inadequate imaging and documentation of OCT, CFP, and FAF to evaluate for toxicity in patients with a history of current or past PPS exposure. This study contributes four cases of PPS maculopathy to the growing literature reporting the phenotypic spectrum of toxicity, including two cases of maculopathy progression following drug cessation. There is a need for evaluations post-cessation due to possible progression of maculopathy, so patients are not treated inappropriately for differential diagnoses.Keywords
This publication has 20 references indexed in Scilit:
- PENTOSAN POLYSULFATE SODIUM-INDUCED PIGMENTARY MACULOPATHY WITH NONLEAKING CYSTOID MACULAR EDEMA SUCCESSFULLY TREATED WITH ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPYRETINAL Cases & Brief Reports, 2020
- Prevalence of Maculopathy Associated with Long-Term Pentosan Polysulfate TherapyOphthalmology, 2020
- Pentosan-associated maculopathy: prevalence, screening guidelines, and spectrum of findings based on prospective multimodal analysisCanadian Journal of Ophthalmology, 2020
- A case of pentosan polysulfate maculopathy originally diagnosed as stargardt diseaseAmerican Journal of Ophthalmology Case Reports, 2020
- Using an excel spreadsheet to convert Snellen visual acuity to LogMAR visual acuityEye, 2020
- Choroidal Neovascularization Associated with Pentosan Polysulfate ToxicityOphthalmology Retina, 2020
- Phenotypic Spectrum of Pentosan Polysulfate Sodium–Associated MaculopathyJAMA Ophthalmology, 2019
- Progressive Maculopathy After Discontinuation of Pentosan Polysulfate SodiumOphthalmic Surgery, Lasers and Imaging Retina, 2019
- Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate SodiumOphthalmology, 2018
- The Royal College of Ophthalmologists’ National Ophthalmology Database study of cataract surgery: report 1, visual outcomes and complicationsEye, 2015